University of Miami's Sylvester Comprehensive Cancer Center

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
University of Miami's Sylvester Comprehensive Cancer Center Announces Participation in DARA BioSciences Breast Cancer Patients for CAPTURE Registry

RALEIGH, NC and MIAMI, FL--(Marketwired - Jul 17, 2013) - The Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine in Miami, FL, is participating in CAPTURE (Compliance and Preference for Tamoxifen Registry) with DARA BioSciences, Inc. , ( NASDAQ : DARA ), a specialty pharmaceutical company focused on oncology supportive care products. The CAPTURE registry is designed to gain valuable insight into adherence to prescribed tamoxifen treatment; patient preference for a liquid formulation of tamoxifen; and prevalence of difficulties in swallowing among breast cancer patients taking tamoxifen tablets.

DARA announced the study at the American Society of Clinical Oncology (ASCO) annual meeting, in June, 2013.

The Sylvester Comprehensive Cancer Center is one of ten leading oncology centers now enrolling patients for this study. CAPTURE was initiated to support the recent launch of Soltamox ® (tamoxifen citrate) oral solution, the only liquid form of tamoxifen available for patients who prefer or need a liquid formulation of tamoxifen. Participating patients currently on tamoxifen therapy for breast cancer are asked to complete an online questionnaire. 

"We are pleased to participate in this study, as the CAPTURE questionnaire explores patient preferences relative to their therapy," said Stefan Glück, MD, PhD , Sylvester Distinguished Professor of Medicine, Division of Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine. "Therapies for breast cancer are long-term, and such courses of therapy pose adherence issues. CAPTURE data potentially could help clinicians improve patient care by learning more about patient preferences."

The CAPTURE registry questionnaire asks patients about their adherence to prescribed tamoxifen therapy, whether they have a preference for a liquid form of the medication (Soltamox, tamoxifen citrate oral solution) or tamoxifen tablets and if they have any swallowing difficulties.

Dr. Glück played a leading role in developing the CAPTURE study design and protocol in conjunction with DARA's Scientific Steering Committee, including Jivesh Sharma, MD, Presbyterian Hospital of Dallas, TX, and CEO of NEXGEN Oncology, Dallas. DARA expects to publish the CAPTURE data and to present it at scientific meetings.

CAPTURE's key objectives are to:

  • Understand patient preference for tamoxifen tablets or an oral tamoxifen liquid solution: Some patients may prefer one dosage form over another for ease of use or for other reasons;
  • Ascertain whether patient participation in choosing their preferred dosage form may lead to better adherence;
  • Correlate adherence to tamoxifen therapy with factors such as, age, ethnicity, history of smoking, alcohol intake, surgery, and radiation therapy;
  • Understand patient adherence to long-term tamoxifen therapy and how it may be affected by swallowing difficulties; and
  • Identify factors that might drive patient preference for the oral liquid form of tamoxifen therapy.

Soltamox (tamoxifen citrate, oral solution) is bioequivalent to, and has the exact same label indications as, the tablet form of tamoxifen. Tamoxifen is indicated for the treatment of ductal carcinoma in situ (DCIS); as adjuvant treatment of node-positive breast cancer; in the treatment of metastatic breast cancer; and for breast cancer risk reduction in high risk women. Currently, there are more than 1.8 million prescriptions of tamoxifen written on an annual basis in the United States. Existing FDA-approved tamoxifen product labeling supports up to five years of treatment. 

About DARA BioSciences, Inc.

DARA is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products.

DARA increased its focus in oncology through its January 2012 acquisition of Oncogenerix, Inc., which holds the exclusive U.S. marketing rights to Soltamox(R) , a novel oral liquid formulation of tamoxifen citrate, which is widely used in the treatment and prevention of breast cancer. Soltamox is the only FDA-approved oral liquid version of tamoxifen citrate and fulfills a vital clinical need for patients who prefer a liquid formulation or cannot tolerate existing solid tablet formulations of this drug. DARA has exclusive U.S. rights to Soltamox through a license from Rosemont Pharmaceuticals, Ltd.

In June 2012, DARA launched its first product, Bionect(R) , a topical treatment for skin irritation and burns associated with radiation therapy. DARA has rights to market Bionect in the US oncology/radiology markets under license from Innocutis. Soltamox was launched formally as DARA's second commercial product in December 2012, coincident in timing with the 35 th Annual San Antonio Breast Cancer Symposium. In late April, 2013, DARA launched its third product, Gelclair ® , an FDA-cleared product for the treatment of oral mucositis for which DARA also has exclusive U.S. commercial rights through a license from Helsinn Group in Switzerland.

DARA is also developing a cancer-support therapeutic compound, KRN5500, for the treatment of chronic chemotherapy-induced peripheral neuropathy (CCIPN) in patients with cancer. This product is an excellent fit with DARA's strategic oncology focus, has successfully completed a Phase 2a clinical trial, and has been designated a Fast Track Drug by the FDA. DARA has created an improved, potentially commercializable formulation of this drug and is in active partnering discussions regarding further clinical development. DARA has also submitted an Orphan Drug Application to the FDA for the use of this drug in painful CCIPN.

For more information please visit our web site at www.darabio.com .

About Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine

Sylvester Comprehensive Cancer Center opened in 1992 to provide comprehensive cancer services to the South Florida community. Together with the 40-bed inpatient hospital, UMHC - University of Miami Hospital & Clinics, Sylvester/UMHC serves as the hub for cancer diagnosis and treatment for UHealth - University of Miami Health System . In 2003, Sylvester expanded its cancer services to patients in Broward and Palm Beach with the opening of Sylvester at Deerfield Beach. A third facility, Sylvester at Kendall, was opened in 2009 to serve patients in southern Miami-Dade county. Our fourth and newest facility, UHealth | Sylvester at Plantation, serves patients in Broward county and includes services such as infusion therapy, imaging, and laboratory services. Since its founding, Sylvester has transformed cancer research and treatment in South Florida and beyond.

Sylvester handles 1,100 inpatient admissions annually, performs more than 2,400 surgical procedures, and treats more than 4,100 new cancer patients. All Sylvester physicians are on the faculty of the Miller School of Medicine , South Florida's only academic medical center.

Today there are more than 305,000 outpatient visits at the cancer center and more than 250 physicians and scientists working together to realize Harcourt Sylvester Jr.'s vision of a comprehensive cancer center. In addition, Sylvester physicians and scientists are engaged in approximately 168 clinical trials and receive more than $49 million annually in research grants.

Safe Harbor Statement

All statements in this news release that are not historical are forward-looking statements within the meaning of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are subject to factors that could cause actual results to differ materially for DARA from those projected. Important factors that could cause actual results to differ materially from the expectations described in these forward-looking statements are set forth under the caption "Risk Factors" in DARA's most recent Annual Report on Form 10-K, filed with the SEC on March 28, 2013. Those factors include risks and uncertainties relating to DARA's ability to timely commercialize and generate revenues or profits from Bionect®, Soltamox®, Gelclair® or other products given that DARA only recently hired its initial sales force and DARA's lack of history as a revenue-generating company, FDA and other regulatory risks relating to DARA's ability to market Bionect, Soltamox, Gelclair or other products in the U.S. or elsewhere, DARA's ability to develop and bring new products to market as anticipated, DARA's current cash position and its need to raise additional capital in order to be able to continue to fund its operations, the current regulatory environment in which DARA develops and sells its products, the market acceptance of those products, dependence on partners, successful performance under collaborative and other commercial agreements, competition, the strength of DARA's intellectual property and the intellectual property of others, the potential delisting of DARA's common stock from the NASDAQ Capital Market, risks and uncertainties relating to DARA's ability to successfully integrate Oncogenerix and other risk factors identified in the documents DARA has filed, or will file, with the Securities and Exchange Commission ("SEC"). Copies of DARA's filings with the SEC may be obtained from the SEC Internet site at http://www.sec.gov . DARA expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DARA's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. DARA BioSciences and the DARA logo are trademarks of DARA BioSciences, Inc.

Media Contacts : David Connolly or Samantha Stenbeck LaVoie Group 617-374-8800 dconnolly@lavoiegroup.com sstenbeck@lavoiegroup.com Corporate Contact : Jenene Thomas DARA BioSciences 908-938-1475 jthomas@darabio.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

24X Options Filing Puts Earnings Bets Before the SEC

Updated Category News Views 15

An earnings release already turns the market into a bar fight; 24X wants to put part of that fight inside a regulated binary-options contract. The Stamford-based exchange has filed a proposed rule change with the SEC for 24X Options, a facility that would offer a conventional options market alongside contracts tied to company performance targets. It is an interesting...

Continue Reading
SecureSpace Plants a Fifth Flag in Miami Beach Storage

Updated Category News Views 111

A small box on Alton Road may carry outsized weight Miami Beach does not hand out cheap, easy real estate wins, which is why SecureSpace's opening at 633 Alton Road deserves a closer look than its modest footprint might suggest. The newly rebranded SecureSpace Miami Beach facility has 18,358 square feet of traditional storage and locker space spread across 536 units, plus...

Continue Reading
Workday’s EU Cloud Move Raises the Sovereignty Bar Again

Updated Category News Views 27

Europe’s sovereignty squeeze just got a lot more concrete for Workday. The company is taking its EU Sovereign Cloud beyond the usual data-residency talking points by planning an Ireland-based operating company, European leadership, and governance intended to keep decisions on the service and customer data inside Europe. For a platform sitting underneath payroll, HR...

Continue Reading
PSEG Declares $0.67 Fourth-Quarter 2026 Cash Dividend

Updated Category News Views 190

A 67-cent utility dividend rarely sets the tape on fire, and that is precisely the point. Public Service Enterprise Group declared a regular fourth-quarter 2026 common-stock dividend of $0.67 per share, payable on or before December 31 to shareholders of record on December 10. For owners of NYSE:PEG, this is the sort of announcement that belongs in the “steady as she...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 34

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 141

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Insider Risk Makes Human Judgment a Security Priority

Updated Category News Views 114

A badge, a password, and a locked gate can all look reassuring right up until the person holding them starts to crack. Signpost Six's new report, The Psychology of Insider Risk, lands on an uncomfortable truth: the most consequential security weakness may not be a system at all. It may be an employee under strain, in conflict, in debt, making a mistake, or being quietly...

Continue Reading
Charter’s $1.5 Billion Tender Tests Debt Discipline

Updated Category News Views 247

Debt cleanup arrives with a hard ceiling Eight far-dated bond issues just got a very specific invitation from Charter Communications: hand them over for cash, but do not expect the company to write a blank check. Charter set final pricing on November 17 for tender offers covering up to $1.5 billion in aggregate consideration, excluding accrued interest and deal expenses....

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 17

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
MAXHUB's Canon Office Test Puts Hybrid Work on Trial

Updated Category News Views 81

Thirty-nine devices scattered through a new Hong Kong office may not sound earth-shaking, but this is how workplace technology actually earns its keep: not under trade-show lights, but when somebody is late to a meeting in another time zone and the room has to work anyway. MAXHUB and Canon Hong Kong have launched the first officially delivered Co-Create 100 project...

Continue Reading

Top 5 Most Recently Viewed Articles

Lexicon Pharmaceuticals Unveils Q3 Financials and Future Plans

Updated Category News Views 138

Third Quarter Financial Highlights of Lexicon Pharmaceuticals Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has disclosed its financial performance for the third quarter of 2025, highlighting significant revenue increases attributed primarily to strategic licensing agreements and product sales. Strategic Partnerships and Revenue Growth In an impressive leap, Lexicon's...

Continue Reading
Growing Innovations in Robotic Dentistry to 2034 and Beyond

Updated Category News Views 178

The Rise of Robotic Dentistry and Its Market Growth The shift towards technological integration in the healthcare sector has begun a revolutionary transformation in dental care. The robotic dentistry market is anticipated to grow significantly, projected to increase from USD 617.39 million in 2024 to an approximate USD 2.24 billion by 2034. This acceleration is based on a...

Continue Reading
Chipotle Lawsuit Update: Key Actions for Shareholders

Updated Category News Views 126

Important Information for Chipotle Shareholders Shareholders of Chipotle Mexican Grill, Inc. (NYSE: CMG) are being advised about an ongoing class action lawsuit that could impact their investments. It is vital for all affected shareholders to take note of critical deadlines and actions they need to undertake to ensure their rights and potential recoveries are protected....

Continue Reading
Quisitive Technology Solutions Reports Q2 2024 Financial Results

Updated Category News Views 144

Quisitive Reports Second Quarter 2024 Financial Results Quisitive Technology Solutions Inc. (“Quisitive” or the “Company”) (TSXV: QUIS, OTCQX: QUISF), a leading provider of Microsoft Cloud and AI solutions, has announced its financial results for the second quarter ending June 30, 2024. Management Commentary Quisitive's CEO, Mike Reinhart, commented, “The first...

Continue Reading
Natural Grocers Reports Strong Fiscal 2024 Performance

Updated Category News Views 231

Natural Grocers by Vitamin Cottage Sees Remarkable Growth in Fiscal 2024 Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) has unveiled its financial results for the fourth quarter and full year of fiscal 2024. The report highlights significant sales and earnings achievements, showcasing the company’s robust performance in a competitive grocery market. Exceptional...

Continue Reading